Reactome | GDC0941 [cytosol]

Schema > ChemicalDrug > Entries

compartment	[Compartment:70101] cytosol
created	[InstanceEdit:2399727] Orlic-Milacic, M, 2012-07-12
crossReference	[DatabaseIdentifier:12020745] Mondo:0004992 [DatabaseIdentifier:9628018] ChEBI:65326
dbId	2399804
disease	[Disease:1500689] cancer
displayName	GDC0941 [cytosol]
inDisease	true
literatureReference	[LiteratureReference:2399831] The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer [LiteratureReference:1358728] Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
maxDepth	1
memberOf	[CandidateSet:R-ALL-2399811] PI3K/mutant PI3K inhibitors [cytosol]
modified	[InstanceEdit:9631716] Wu, G, 2018-12-12
name	GDC0941 pictrelisib
referenceEntity	[ReferenceTherapeutic:iuphar.ligand:5682] pictilisib [Guide to Pharmacology:5682]
schemaClass	ChemicalDrug
stId	R-ALL-2399804

(hasMember)

Cite Us!